Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2008-09-29
2011-11-01
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007230
Reexamination Certificate
active
08048621
ABSTRACT:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-1R kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF-1R kinase inhibitors.
REFERENCES:
patent: 6448086 (2002-09-01), Khosravi
patent: 6617121 (2003-09-01), Garcia
patent: 7081340 (2006-07-01), Baker
patent: 7241444 (2007-07-01), Goetsch
patent: 2004/0018191 (2004-01-01), Wang
patent: 2004/0106605 (2004-06-01), Carboni
patent: 2004/0132097 (2004-07-01), Bacus
patent: 2004/0209930 (2004-10-01), Carboni
patent: 2005/0019785 (2005-01-01), Baker
patent: 2005/0136063 (2005-06-01), Wang
patent: 2005/0249730 (2005-11-01), Goetsch
patent: 2005/0266496 (2005-12-01), Gilon
patent: 2006/0018910 (2006-01-01), Gualberto
patent: 2006/0046249 (2006-03-01), Huang
patent: 2006/0140960 (2006-06-01), Wang
patent: 2006/0211060 (2006-09-01), Haley
patent: 2007/0059785 (2007-03-01), Bacus
patent: 2007/0065858 (2007-03-01), Haley
patent: 2007/0141621 (2007-06-01), Agus
patent: 2007/0212738 (2007-09-01), Haley
patent: 2007/0243194 (2007-10-01), Hariharan
patent: 2007/0265185 (2007-11-01), Bouamrani
patent: 2007/0270505 (2007-11-01), Bunn
patent: 2008/0085519 (2008-04-01), Gabrin
patent: 2008/0090233 (2008-04-01), Garcia
patent: 2008/0312260 (2008-12-01), Haley
patent: 03078662 (2003-09-01), None
patent: 2004046386 (2004-06-01), None
patent: 2004063709 (2004-07-01), None
patent: 2004065602 (2004-08-01), None
patent: 2004071572 (2004-08-01), None
patent: 2004111273 (2004-12-01), None
patent: 2005017493 (2005-02-01), None
patent: 2005037836 (2005-04-01), None
patent: 2005052005 (2005-06-01), None
patent: 2005061541 (2005-07-01), None
patent: 2005067667 (2005-07-01), None
patent: 2005070020 (2005-08-01), None
patent: 2005094332 (2005-10-01), None
patent: 2005097800 (2005-10-01), None
patent: 2005099363 (2005-10-01), None
patent: 2005107803 (2005-11-01), None
patent: 2005117553 (2005-12-01), None
patent: 2006099396 (2006-09-01), None
patent: 2006101925 (2006-09-01), None
patent: 2007028146 (2007-03-01), None
patent: 2007035744 (2007-03-01), None
patent: 2007075554 (2007-07-01), None
patent: 2007141626 (2007-12-01), None
patent: 2008104344 (2008-09-01), None
patent: 2008115470 (2008-09-01), None
patent: 2008144345 (2008-11-01), None
patent: 2010120966 (2010-10-01), None
Glinsky et al, 2004, J Clin Invest, 113: 913-923.
Oesterreich, S et al, 1996 (Clin Cancer Res, 2: 1199-1206.
Vandesompele J et al, 2003 (Oncogene, 22(3): 456-60).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Ritchie et al, 2001, Am J Hum Genet, 69: 138-147.
Laasko, M. et al. (2006) Clinical Cancer Research: An official Journal of the American Association for Cancer Research 12: 14 part 1, 4185-4191.
Lan, M. et al. (2004) Carcinogenesis 25(12): 2385-2395.
Larrson, O. et al. (2005) British Journal of Cancer 92, 2097-2101.
Lee, J. M. et al. (2006) Journal of Cell Biology 172:7, 973-981.
Lemoine, N.R. et al. (1992) Br. J. Cancer 66:1116-11121.
Letters to Journal (2005) J of Clin. Onco. 23, No. 4,Feb. 1, 2005; pp. 923-924.
Lippman, S.M. et al. (2005) Clin. Cancer Res. 11(17):6097-6099.
Locascio, A. et al. (2002) The Journal of Biological Chemistry 277(41): 38803-38809.
Lu, Z., et al., (2003) Cancer Cell. 4(6):499-515.
Markl, J. (1991) Journal of Cell Science 98: 261-264.
Matar, P. et al. (2004) Clin. Cancer Res. 10:6487-6501.
Matei, D. et al. (2006) Oncogene 25: 2060-2069.
Mitsiades, C.S., et al. (2006) Cancer Cell 5, 231-230.
Modern Pharmacology, 1990, Eds. Craig and Stitzel, Publishers, Little, Brown and Company, Chapter 60, pp. 776-778.
Moll, R. et al. (1982) Cell 31: 11-24.
Moody, S.E. (2005) Cancer Cell vol. 8, Sep. 2005, pp. 197-209.
Moon, H. et al (2001) Gynecologic Oncology 81:355-359.
Mulvihill, M.J. et al. (2009) Future Med. Chem. 1(6): 1153-1171.
Natalwala, A. et al. (2008) World J. Gastroenterol 14(24): 3792-3797.
Nolan, G.P. (2007) Nature Chemical Biology 3(4): 187-191.
Nunes, M. et al; (2004) Molecular Cancer Therapeutics, 3(1):21-27.
Ohira, T. et al. (2003) PNAS 100(18):10429-10434.
Osbourne, R. (2008) Nature Biotechnology 26(7):719-720.
Oshima, RG (2002) Cell Death and Differentiation 9: 486-492.
Pece, S. et al. (275) J Biol Chem 275 (52): 41227-41233.
Perez-Solar, R. et al. (2003) Lung Cancer 41 (Suppl. 2), p. S72, Abstract O247.
Peinado, H. et al, (2007) Nature Rev. Cancer, 7:415-428.
Pena, C. et al. (2005) Human Molecular Genetics 4(22).
Pollack, M.N., et al. (2004) Nature Reviews/Cancer 4, 505-518.
Pollack, M. (2009) Nature Reviews Cancer 8: 915-928.
Qian, X. et al (2004) EMBO 23:1739-1748.
Ramaekers, F.C.S. et al. (1987) Acta Histochemica Suppl. 34: 45-56.
Ramaekers, F.C.S. et al. (1983) Proc. Natl. Acad. Sci. USA 80: 2618-2622, May 1983, Cell Biology.
Ransohoff, D.F. (2003) Science 299, 1679-1680, downloaded from www.Sciencemag.org on Mar. 11, 2009.
Rasmussen, A., et al. (1998) Breast Cancer Research and Treatment 47(3): 219-233.
Richardson, F. et al. (2009) International Association for the Study of Lung Cancer, 13th World Conference on Lung Cancer, Jul. 31-Aug. 4, 2009, Moscone West, San Francisco, USA. “Comparison of E-cadherin IHC Status with Clinical Outcomes from Erlotinib in the Non Small Cell Lung Cancer (NSCLC) Clinical Trial NCIC CTG BR.21” e-Poster: PD7.2.5. Congress: WCLC 2009; 29 pages.
Riedemann, J. et al. (2006) Endocrine-Related Cancer 13, s33-s43.
Rosivatz, E. et al. (2002) American Journal of Pathology 161(5): 1881-1891.
Rukstalis, J.M. et al. (2006) Endocrinology 147(6): 2997-3006.
Ryan, P.D., et al. (2008) The Oncologist 13, 16-24 *downloaded from www.TheOncologist.com on May 29, 2008.
Sabatini, P. et al. (2009) Clin Cancer Res 15(9): 3058-3067.
Sakurai, H. et al.; (1997) Proc. Natl. Acad. Sci. USA, 94:6279-6284.
Samani, A.A. et al. (2007) Endocrine Reviews 28(1): 20-47.
Sarrio, D. et al. (2008) Cancer Research 68:4, 989-997.
Savagner, P. (2001) Bioessays 23:912-923.
Schaafsma, HE (May 1993) J. Pathol. 170(1): 77-86.
Schlessinger, K. et al. (2004) Nature Cell Biology 6(10):913-915.
Schussler, M.H. et al. (Mar. 1992) Am. J. Pathol. 140(3): 559-568.
Shrader, M. et al. (2007) Mol Cancer Ther 6(1): 277-285.
Shen, X. et al. (2004) Amer J Path 165 (4): 1315-1329.
Spaderna, S. et al. (2008) Cancer Res 68(2): 537-544.
“Sternberg, D., TAT Meeting, 8th International Symposium on Targeted Anticancer Therapies, Mar. 4-6, 2010. Bethesda, MD, USA, “The Development and Application of EMT Biomarkers in the Therapy of Solid Tumors”; 37 slides.”
Struz, F. et al. (2002) Kidney Interantional 61:1714-1728.
Suggitt, M. et al. (2005) Clinical Cancer Res 11: 971-981.
Sun, T.T. (1984) Cancer Cell 1, The Transformed Phonotype vol. 1; 169-176, Levine, A. et al. eds.; Cold Spring Harbor Laboratory.
Suto, K. et al. (1999) J. Can.Res.Clin. Oncol. 125:83-88.
Takenaka, K. et al. (2005) Cancer Epidemiology Biomakers & Prevention 14(8) :1972-1975.
Takkunen, M. (2006) Journal of Histochemistry & Cytochemistry 54(11): 1263-1275.
Tejeda, M.L. et al. (2006) Clinical Cancer Research 12(9): 2676-2688, May 1, 2006.
Thiery, J.P. (2002) Nat. Rev. Cancer 2:442-454.
Thomas, P.A. et al. (
Buck Elizabeth A.
Haley John D.
OSI Pharmaceuticals, LLC
OSI Pharmaceuticals, LLC
Stewart Alexander A.
Yao Lei
Yu Misook
LandOfFree
Biological markers predictive of anti-cancer response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological markers predictive of anti-cancer response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological markers predictive of anti-cancer response to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302909